How are 4 prominent NZX healthcare penny stocks performing?

3 min read | October 19, 2021 08:29 PM NZDT | By Neha Simpy

Highlights

  • Market analysts are of the opinion that the healthcare space is all set to witness growth, which might give potential to small companies to thrive upon.
  • Rua Bioscience released its ASM presentation highlighting its four key pillars.
  • Smaller healthcare companies can take the market by storm with their successful trials or launch of new products.

Healthcare is one of those few sectors which saw a boom amid the coronavirus pandemic, which otherwise caused a ruckus in every sphere of life worldwide.

On 19 October, benchmark, the S&P/NZX 50 Index, last traded at 13,065.92 points, up by 0.52%. Simultaneously, the S&P/NZX All Health Care last traded, up by 0.87% at 3,352.69 points.

With the economy returning to normal, market analysts are of the opinion that the healthcare space is all set to witness growth ahead.  There is a lot of potential for small organisations to cash in on it.

On the given backdrop, let’s now take a peek at 5 NZX healthcare penny stocks.

NZX healthcare penny stocks- TRU, PHL, RUA, BLT

            Image source: © 2021 Kalkine Media New Zealand Ltd, data source- EODHD/Others

TruScreen Group Limited (NZX:TRU)

Medical device entity TruScreen Group Limited published its Annual Meeting presentation on 7 September.

During the meeting, FY21 results and strategy for FY22 closing March 2022 were discussed, which outlined continuous product improvement and innovation, rapid expansion in China and constant development in other markets.

On 19 October, by the end of the trading session, TruScreen was flat at NZ$0.064.

Related read; TruScreen (NZX:TRU) releases its annual meeting presentation for FY21

Promisia Healthcare Limited (NZX:PHL)

Healthcare services provider Promisia Healthcare Limited runs elderly care facilities.   

By the end of August, the Company informed the market about finalising its quarterly covenant reporting (correlated to a requirement towards EBITDA/interest cover to be no less than two times the interest price). The Company informed that Promisia was in violation of one of the two banking covenants during the June quarter.

By the close of the market session, on 19 October, Promisia was unchanged at NZ$0.001.

Did you read; FY21 Results: TAH, PHL & GEN Show Growth Despite COVID-19 Pandemic

Rua Bioscience Limited (NZX:RUA)

NZ-domiciled therapeutic cannabis company Rua Bioscience Limited provided an ASM presentation to the market.

The Meeting included the Chairman’s commentary and reflection on FY21 that went by, which had proved transformational for the Company.

The meeting further discussed its strategy and four major pillars.

-Developing unique product and plant IP.

- Next, taking the IP and creating new products and markets.

- Then lay emphasis on optimising cultivation and processing.

- Lastly, development of their individuals.

On 19 October, Rua ended the day’s session decreasing by 2.44% at NZ$0.4.

Did you miss reading; Will Rua Bioscience’s (NZX:RUA) growth strategies pay off well?

Blis Technologies Limited (NZX:BLT)

Biotech entity developing advanced probiotics is based in Dunedin.

On 14 September, the Company provided an update on issued performance share rights without consideration to a few members of upper management. These performance share rights received directors’ nods on 10 September.

Blis closed the market session at NZ$0.061, decreasing by 1.61%, as on 19 October.

Bottom Line

Penny stocks are usually volatile in nature, however, such stocks from the healthcare sector could surprise the market. Relatively, smaller healthcare companies can take the market by storm with their successful trials or launch of new products, followed by a surge in their prices.


Disclaimer

The content on this website, including, but not limited to, any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (“Content”) is a service provided by Kalkine Media New Zealand Limited (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide financial advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests users seek financial advice from a financial advice provider, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all liability to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without any express or implied warranties of any kind. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit a source wherever it is indicated or is found to be necessary or desirable.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.